Association on cardiovascular interventions of PCS Current status of drug-eluting stents and drug-eluting balloons in patients with stable coronary artery disease: An expert consensus document of the Association for Percutaneous Cardiovascular Interventions and Polish Cardiac Society

Witkowski, Adam; Opolski, Maksymilian P.; Dudek, Dariusz; Lesiak, Maciej; Legutko, Jacek; Wojakowski, Wojciech; Ochała, Andrzej; Maciejewski, Paweł; Deptuch, Tomasz; Araszkiewicz, Aleksander; Ciećwierz, Dariusz

doi:10.5114/pwki.2011.21188

Cited by 2 publications

(3 citation statements)

References 119 publications

(149 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though it has been reported that atorvastatin concentration as low as 0.1 μM was effective in suppressing the growth of smooth muscle cells, , controlled release of atorvastatin to provide such low concentration has not been demonstrated. Considering that the drug loading in current stents commonly is 100 μg/cm 2 or greater, the capability to effectively deliver drug using much lower loading is expected to contribute to minimizing system toxicity while inhibiting HCASMC growth. , …”

Section: Resultsmentioning

confidence: 99%

“…Considering that the drug loading in current stents commonly is 100 μg/cm 2 or greater, 6 the capability to effectively deliver drug using much lower loading is expected to contribute to minimizing system toxicity while inhibiting HCASMC growth. 59,60 Overall, the combination of nanocoating surface and drug release substantially reduced the viability and proliferation of HCASMC on PDE31 coated atorvastatin. For example, at 10 μg/cm 2 , the MTT and BrdU activities of HCASMC were suppressed to 56.7% and 55.6% of the control, respectively.…”

Section: ■ Results and Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vapor-Deposited Nanocoatings for Sustained Zero-Order Release of Antiproliferative Drugs

Zhi

Mao

2020

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Drug-eluting stents have been widely used in the treatment of coronary heart diseases, but the long-term efficacy has been dependent on the control of drug release kinetics. Though evenly distributed release with minimal burst release is much desired for the antiproliferative drugs used on stents, strategies for sustained zero-order release have not been specifically identified. We investigated vapor-based fabrication of polymer nanocoatings for the encapsulation of antiproliferative drugs. Drug release kinetics was regulated by adjusting the composition and thickness of the nanocoatings. Zero-order release of atorvastatin and sirolimus for 30 days was achieved using a poly(2-dimethylamino ethyl methacrylate-co-ethylene glycol diacrylate) (PDE) nanocoating with a monomer/cross-linker molar ratio of 0.78. The drug release rate was modulated using drug dose and coating thickness. The combination of coating surface and drug release suppressed the viability and proliferation of human coronary artery smooth muscle cells to below 57% at dose density as low as 10 μg/cm2. The PDE nanocoatings also reduced surface platelet adhesion without detrimental effect on red blood cells. The findings of this study demonstrate the potential of applying vapor-deposited polymer nanocoatings in modulating the release kinetics and thus improving the therapeutic efficacy of drug-eluting stents.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: ■ Results and Discussionmentioning

confidence: 99%

Vapor-Deposited Nanocoatings for Sustained Zero-Order Release of Antiproliferative Drugs

Zhi

Mao

2020

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

show abstract

“…Similar recommendations for DES use in STEMI (class IIa, earlier IIb) are present in the guidelines of the American cardiology societies [ 41 ]. Experts of the Polish Society of Cardiology do not preclude the use of DES, whose efficacy is proved in a selected population of STEMI patients [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

The use of drug-eluting stents in acute myocardial infarction – is the battle coming to an end? From despair to acceptance

Kübler¹,

Reczuch²

2013

pwki

View full text Add to dashboard Cite

The large-scale use of drug-eluting stents (DES) in elective percutaneous coronary interventions resulted in a significant reduction of restenosis and the need for repeat revascularization, compared to bare-metal stents (BMS) and balloon angioplasty. The position of DES used during primary percutaneous coronary intervention was not so well established. Based on the trials including the general population of patients, an increased risk of stent thrombosis was indicated, particularly late after implantation, which may be associated with increased mortality. A number of randomized clinical trials have compared first generation DES with BMS in acute ST-segment elevation myocardial infarction (STEMI). In most of them increased mortality after DES implantation was not confirmed, with demonstrated reduction of repeat revascularizations. However, long-term follow-up of these studies and the results from non-randomized “real world” registries are equivocal. A new generation of DES has been present on the market for several years. They have modern designs, are covered with more neutral polymers and release new drugs. The new generation DES have a better safety and efficacy profile, including a population of patients with acute STEMI, than the first generation stents. This paper is a review of randomized controlled trials, meta-analyses and registries, comparing DES with BMS in patients with acute STEMI. Attention was drawn to the current position and the role of new generation DES, which may prove to be a safe and effective choice in this population of patients.

show abstract

Association on cardiovascular interventions of PCS Current status of drug-eluting stents and drug-eluting balloons in patients with stable coronary artery disease: An expert consensus document of the Association for Percutaneous Cardiovascular Interventions and Polish Cardiac Society

Cited by 2 publications

References 119 publications

Vapor-Deposited Nanocoatings for Sustained Zero-Order Release of Antiproliferative Drugs

Vapor-Deposited Nanocoatings for Sustained Zero-Order Release of Antiproliferative Drugs

The use of drug-eluting stents in acute myocardial infarction – is the battle coming to an end? From despair to acceptance

Contact Info

Product

Resources

About